Search Results
A Day in LLS History
On October 20, 1944, Robert “Robbie” Roesler de Villiers was only 16 years old when he died from leukemia. Robbie’s parents, Rudolph and Antoinette, were stricken with grief and frustrated by the lack of effective treatments for what was then considered a hopeless disease.
After five years of mourning their son, they started a fundraising and education organization in his name. The Robert Roesler de Villiers Foundation had only a few volunteers and a tiny budget.
Omacetaxine mepesuccinate
Omacetaxine mepesuccinate is FDA approved for the treatment of adult patients with chronic or accelerated phase chronic myeloid leukemia (CML) with resistance and/or intolerance to two or more tyrosine kinase inhibitors (TKI).
The effectiveness of omacetaxine mepesuccinate was evaluated using a combined group of patients whose cancer progressed after previous treatment with two or more TKIs. All participants were treated with omacetaxine mepesuccinate.
Acalabrutinib
Acalabrutinib is a kinase inhibitor indicated:
- In combination with bendamustine and rituximab for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL) who are ineligible for autologous hematopoietic stem cell transplantation (HSCT).
- For the treatment of adult patients with MCL who have received at least one prior therapy.
- For the treatment of adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).
Why We Love Nurses (And You Should Too!)
It makes sense that at diagnosis and throughout treatment, someone diagnosed with a blood cancer will look around them for answers or support.
Impact of Health Insurance on Mortality for Children and AYAs Newly Diagnosed with a Blood Cancer: A Population-Based Multistate Evaluation
Lacking continuous insurance is a key barrier to access to timely care. This study will provide the first evidence of whether insurance continuity provides a survival benefit, and how Medicaid expansion under the Affordable Care Act affects insurance continuity and the associated downstream changes in survival for children, adolescents, and young adults with blood cancers. This study will inform policy interventions toward increasing access and reducing disparities in blood cancer outcomes.Targeting AML
Not for lack of trying, we’ve seen very little progress over the past 40 years in treating acute myeloid leukemia (AML), an aggressive and deadly blood cancer. But we’re finally starting to see the needle move and The Leukemia & Lymphoma Society (LLS) is playing a leading role in going on the offensive against the disease.
#ASH15 Day 3: Big Advances in Treating Chronic Lymphocytic Leukemia
John Byrd, M.D., of the Ohio State University Comprehensive Cancer Center, is one of the world’s renowned scientists in the field of blood cancer. LLS has been supporting his work for the better part of two decades. While Byrd has, of late, turned his attention to the problem of finding better therapies for patients with acute myeloid leukemia (AML), it is in chronic lymphocytic leukemia (CLL) that he has made his mark.
Doxorubicin
Doxorubicin is FDA approved to treat people who have some kinds of blood cancer, including acute lymphoblastic leukemia, acute myeloblastic leukemia, and Hodgkin and non-Hodgkin lymphoma.
Hydroxyurea
Hydroxyurea is FDA approved to treat people who have chronic myelocytic leukemia and some other blood cancers, including essential thrombocythemia and polycythemia vera. Hydroxyurea may cause temporary loss of hair in some people. After treatment has ended, normal hair growth should return, although the new hair may be a slightly different color or texture.
Methotrexate
Methotrexate is FDA approved, alone or with other drugs, to treat people who have acute lymphoblastic leukemia (ALL) that has spread to the central nervous system (CNS) or to prevent ALL from spreading to the CNS. It is also FDA approved to treat people who have advanced non-Hodgkin lymphoma and advanced mycosis fungoides. It may also be used to treat people with other types of blood cancer.
Surviving AML: The Long Road Back
“Hola,” I said playfully, as I answered my cell phone on a beautiful Saturday -- April 21, 2012. “This is Dr. so and so. I’m calling because your blood work from yesterday is all out of whack.” “What do you mean, ‘Out of whack?’” “Your white blood cell count is high,” he said. “What’s high? “It's at 63,000.” “And what's it supposed to be?” “10,000.”
Topotecan
Topotecan is an FDA-approved cancer drug that is used to treat people who have certain types of cancer including acute myeloid leukemia and acute lymphoblastic leukemia. This drug may cause a temporary loss of hair in some people. After treatment with topotecan has ended, normal hair growth should return.
Researchers Share Key Career Advice with LLS College Club Members
I recently had the privilege of moderating an LLS on Campus Researcher Panel attended by LLS college club members from nearly 30 universities across the country. These clubs bring together students interested in pursuing health-related careers and provide opportunities to hear from scientists working to better understand and treat blood cancers.